Skip Navigation Links
 



                     


 



   
    Learn More     Subscribe    
Join Now!      Login
 
 
 
FREE HEALTH
NEWSLETTER
 
 
Stevia - FDA Poll
Should stevia be approved as a sweetener by the FDA?
 
 
 
 
W
hat Doctors Don't Tell You
 


Hope for Alzheimer's?

© What Doctors Don't Tell You

The following is one in an ongoing series of columns entitled What Doctors Don't Tell You by What Doctors Don't Tell You . View all columns in series

Since then, three other drugs have come onto the market, all of which attempt to do the same trick of increasing acetylcholine in the brain. As expected, these drugs are all deadly rivals. Pfizer's Aricept (donepezil), has an advertising tagline that says 'when Alzheimer's hits home, Aricept can help'; Novartis' Exelon (rivastigmine) claims to be 'another step forward against Alzheimer's disease'; and Shire Pharmaceuticals/Janssen's Reminyl (galantamine) sells itself with the somewhat vague tagline 'Reminyl is now'.

So far, Pfizer is the only manufacturer to have threatened a lawsuit against the recent NICE ruling that none of these drugs is really worth taking in the early stages of AD. Will the drugmaker win their case? Our prediction is no-and, frankly, because the evidence is stacked against them.

The only large-scale, truly independent clinical trial of Pfizer's Aricept was carried out by a team of British researchers at the University of Birmingham. In a double-blind trial that lasted for more than two years, Aricept was tested head-to-head against a placebo in over 500 patients who had mild-to-moderate AD.

The study's conclusions? Aricept works, but its benefits are very small-"below minimally relevant thresholds" (Lancet, 2004; 363: 2105-15). As study director Professor Richard Grey stated in the report: "Patients and their families would probably notice no difference if the drug was stopped."

What's more, even clinical trials funded by the drug companies them-selves failed to show much benefit with any of their products. For example, Oxford University researchers recently scrutinized data from 24 separate Pfizer-sponsored Aricept trials, involving more than 5000 patients at different stages of AD, and concluded that "the treatment effects are small and are not always apparent in practice". Add to that the strong likelihood of "many adverse events" such as nausea, vomiting, diarrhoea, muscle cramps, dizziness, fatigue and anorexia, and it's little wonder that there's what the researchers politely refer to as a "debate" over whether Aricept is worth a candle (Cochrane Database Syst Rev, 2006; 1: CD001190).

The same Oxford scientists have also examined another of Pfizer's claims-which is also supported by the strictly independent Alzheimer's Society-that Aricept helps prevent the onset of AD, stopping what is classified as 'mild cognitive impairment' (MCI) from turning into full-blown Alz-heimer's. The researchers' conclusion? According to their report: "There is no evidence to support the use of Aricept for patients with MCI. The putative benefits are minor, short-lived and associated with significant side effects" (Cochrane Database Syst Rev, 2006; 3: CD006104).

What of Aricept's two other rivals, however? Again, independent studies of the clinical data have exposed the drug companies' marketing hype.

With MCI, for example, Polish researchers concluded earlier this year that the efficacy of all three cholinesterase-blocking drugs was "questionable", especially given the high incidence of side-effects, some of which-as in the case of Reminyl-apparently can be fatal (Neurol Neurochir Pol, 2007; 41: 13-21).

As for full-blown AD itself, three groups of independent researchers all agree that the three drugs, although having slightly different modes of action, all produce broadly similar effects-or rather, a lack of effects. Their benefit to Alzheimer patients is variously described as "not large" (Cochrane Database Syst Rev, 2006; 1: CD005593), "limited" (Tijdschr Psychiatr, 2006; 48: 17-26) and "small" (Drugs Aging, 2007; 24: 155-67).

Add your comment   CONTINUED      Previous   1  2  3  4  5  Next   
About The Author
What Doctors Don’t Tell You is one of the few publications in the world that can justifiably claim to solve people's health problems - and even save lives. Our monthly newsletter gives you the facts you won't read anywhere else about what works, what doesn't work and what may harm you in both orthodox and alternative medicine. We'll also tell you how you can prevent illness.......more
 
Share   Facebook   Buzz   Delicious   Digg   Twitter  
 
 
 
 
 
 
From Our Sponsor
 
 
 
 
 
 
Featured Events
Wellness Inventory Certification Training - Level I
     February 18-May 20, 2014
     Los Angeles, CA USA
 
Additional Calendar Links
 
Wellness, Communicating, dimension!

Search   
Home       Wellness       Health A-Z       Alternative Therapies       Find a Practitioner       Healthy Products       Bookstore       Wellness Inventory
Healthy Kitchen       Healthy Woman       Healthy Man       Healthy Child       Healthy Aging       Wellness Center       Nutrition Center       Fitness Center
Free Newsletter      What Doctor's Don't Tell You      Stevia.com      Discount Lab Tests      First Aid      Global Health Calendar      Privacy Policy     Contact Us

Disclaimer: The information provided on HealthWorld Online is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.